Keywords: Agenus, GlaxoSmithKline, QS-21 Stimulon, License, Nuron Biotech, Akshaya Bio, Vaccines, HCV, CNS diseases

Agenus expands deal with GlaxoSmithKline; Nuron in-licenses vaccines

Article | 06 March 2012

Print This

US biotech firm Agenus (Nasdaq: AGEN) says it has amended the QS-21 license and manufacturing agreement with UK pharma giant ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in